<DOC>
	<DOC>NCT00482014</DOC>
	<brief_summary>The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.</brief_summary>
	<brief_title>A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inoperable non small cell lung cancer No weight loss greater than 10% in 3 months prior to enrolling in trial Adequate kidney function Adequate liver function Adequate lung function Previous surgery to remove lung tumor Previous chemotherapy or radiation therapy or lung cancer Inability to take vitamin supplementation Heart attack within past 6 months Active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>